Zevra Therapeutics, Inc. ZVRA Fair value adjustment related to warrant and CVR liability
Fair value adjustment related to warrant and CVR liability at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept zvra:FairValueAdjustmentRelatedToWarrantAndCVRLiability.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s fair value adjustment related to warrant and cvr liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s fair value adjustment related to warrant and CVR liability?
- Zevra Therapeutics, Inc. (ZVRA) reported fair value adjustment related to warrant and CVR liability of -$968K in Q1 2026.
- How has Zevra Therapeutics, Inc.'s fair value adjustment related to warrant and CVR liability changed year-over-year?
- Zevra Therapeutics, Inc.'s fair value adjustment related to warrant and CVR liability increased by 80.1% year-over-year, from -$4.87M to -$968K.
- What does fair value adjustment related to warrant and CVR liability mean?
- Represents non-cash gains or losses resulting from the periodic revaluation of financial instruments such as warrants or contingent value rights. These adjustments reflect market-based changes in the fair value of liabilities that are sensitive to the company's stock price or performance milestones.